Anagram Therapeutics · Other
Developing novel orally delivered enzyme therapeutics engineered for rare and life-threatening malabsorption diseases.
Amount
$250M
Round
Other
Valuation
—
Announced
May 2024
Investors
Lead investor
Blackstone Life SciencesNotes
auto-discovered via firecrawl